

Joaquim Ferreira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9072400/publications.pdf>

Version: 2024-02-01

324
papers

12,989
citations

31976

53
h-index

32842

100
g-index

335
all docs

335
docs citations

335
times ranked

13517
citing authors

#	ARTICLE	IF	CITATIONS
1	Caregiver Burden in Late-Stage Parkinsonism and Its Associations. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 110-120.	2.3	18
2	Anticoagulation therapy in patients with post-operative atrial fibrillation: Systematic review with meta-analysis. <i>Vascular Pharmacology</i> , 2022, 142, 106929.	2.1	2
3	Frequency and Characteristics of Psychosis in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Parkinson's Disease</i> , 2022, 12, 85-94.	2.8	2
4	An MDS Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , 2022, 37, 25-35.	3.9	19
5	Frequency of dementia in Parkinson's disease: A systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120077.	0.6	19
6	COMT Inhibitors in the Management of Parkinson's Disease. <i>CNS Drugs</i> , 2022, 36, 261-282.	5.9	18
7	Low risk of haematomas with intramuscular vaccines in anticoagulated patients: a systematic review with meta-analysis. <i>Thrombosis Journal</i> , 2022, 20, 9.	2.1	2
8	Profile of cognitive impairment in late-stage Parkinson's disease. <i>Brain and Behavior</i> , 2022, 12, e32537.	2.2	5
9	Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone) Trial. <i>Trials</i> , 2022, 23, 148.	0.784314	0
10	Postural abnormalities in Asian and Caucasian Parkinson's disease patients: A multicenter study. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 91-98.	2.2	7
11	Neuroimaging cerebrovascular biomarkers in Parkinson's disease. <i>Neuroradiology Journal</i> , 2022, 35, 490-496.	1.2	1
12	Potential drug-drug interactions in acute poisonings managed in the intensive care unit: Occurrence, risk factors and relationship to patient severity on admission. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 337-345.	2.5	3
13	Systematic reviews and meta-analysis published in indexed Portuguese medical journals: time trends and critical appraisal. <i>BMC Medical Research Methodology</i> , 2022, 22, 105.	3.1	1
14	Adverse Events of Physiotherapy Interventions in Parkinsonian Patients. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 744-750.	1.5	3
15	The sham effect of invasive interventions in chronic coronary syndromes: a systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 223.	1.7	2
16	Smartphone-Based Body Location-Independent Functional Mobility Analysis in Patients with Parkinson's Disease: A Step towards Precise Medicine. <i>Journal of Personalized Medicine</i> , 2022, 12, 826.	2.5	1
17	European Academy of Neurology/Movement Disorder Society European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies. <i>Movement Disorders</i> , 2022, 37, 1360-1374.	3.9	49
18	European Academy of Neurology/Movement Disorder Society European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies. <i>European Journal of Neurology</i> , 2022, 29, 2580-2595.	3.3	22

#	ARTICLE	IF	CITATIONS
19	Assessment Tools to Evaluate Motor Function in People with Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 13-24.	2.6	2
20	The Interaction between <i>HLA-DRB1</i> and Smoking in Parkinson's Disease Revisited. <i>Movement Disorders</i> , 2022, 37, 1929-1937.	3.9	4
21	Aspirin for Primary Cardiovascular Prevention in Patients with Family History of Cardiovascular Disease: Meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 871-873.	2.6	1
22	Cross-cultural adaptation and validation of the Swallowing Disturbance Questionnaire and the Sialorrhea Clinical Scale in Portuguese patients with Parkinson's disease. <i>Logopedics Phoniatrics Vocology</i> , 2021, 46, 163-170.	1.0	5
23	Speech intelligibility of Parkinson's disease patients evaluated by different groups of healthcare professionals and naïve listeners. <i>Logopedics Phoniatrics Vocology</i> , 2021, 46, 141-147.	1.0	5
24	Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 97-106.	4.0	23
25	The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis. <i>Clinical Research in Cardiology</i> , 2021, 110, 183-193.	3.3	27
26	Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 366-382.	3.4	14
27	Unsupervised Walking Activity Assessment Reveals COVID-19 Impact on Parkinson's Disease Patients. <i>Movement Disorders</i> , 2021, 36, 531-532.	3.9	4
28	Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 577-588.	2.4	5
29	Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities. <i>BMC Medical Research Methodology</i> , 2021, 21, 42.	3.1	8
30	Factors Associated with Health-Related Quality of Life in Late-Stage Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 563-570.	1.5	16
31	Kinematic and Clinical Outcomes to Evaluate the Efficacy of a Multidisciplinary Intervention on Functional Mobility in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 637620.	2.4	4
32	Parkinson's Disease Drug Development Since 1999: A Story of Repurposing and Relative Success. <i>Journal of Parkinson's Disease</i> , 2021, 11, 421-429.	2.8	7
33	Botulinum toxin type A versus anticholinergics for cervical dystonia. <i>The Cochrane Library</i> , 2021, 2021, CD004312.	2.8	1
34	Antithrombotic Therapy Recommendations in the European Society of Cardiology Guidelines: How Robust Are the Randomized Controlled Trials Underpinning Them?. <i>TH Open</i> , 2021, 05, e125-e133.	1.4	1
35	Clinical Utility of Opicapone in the Management of Parkinson's Disease: A Short Review on Emerging Data and Place in Therapy. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2021, Volume 11, 29-40.	1.3	1
36	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 1964-1967.	3.9	4

#	ARTICLE	IF	CITATIONS
37	Clinical Diagnostic Criteria Have a High Impact on the Frequency of Dementia in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 652424.	2.4	2
38	Does Parkinson's Disease Increase the Risk of Atrial Fibrillation? Insights From Electrocardiogram and Risk Scores From a Case-Control Study. <i>Frontiers in Neurology</i> , 2021, 12, 633900.	2.4	5
39	miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 661461.	3.7	18
40	Cardiovascular and cerebrovascular risk markers in Parkinson's disease: Results from a case-control study. <i>European Journal of Neurology</i> , 2021, 28, 2669-2679.	3.3	4
41	Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 25-31.	2.2	10
42	Moving towards Integrated and Personalized Care in Parkinson's Disease: A Framework Proposal for Training Parkinson Nurses. <i>Journal of Personalized Medicine</i> , 2021, 11, 623.	2.5	18
43	Feasibility and Safety of Telerehabilitation for Physiotherapy Interventions in Movement Disorders Patients. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1144-1147.	1.5	6
44	Feasibility of a Mobile-Based System for Unsupervised Monitoring in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 4972.	3.8	9
45	Validation of quantitative gait analysis systems for Parkinson's disease for use in supervised and unsupervised environments. <i>BMC Neurology</i> , 2021, 21, 331.	1.8	11
46	The Parkinson's Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson's Disease in Patients and their Carers. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1309-1323.	2.8	8
47	(Dys)Prosody in Parkinson's Disease: Effects of Medication and Disease Duration on Intonation and Prosodic Phrasing. <i>Brain Sciences</i> , 2021, 11, 1100.	2.3	4
48	Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1019-1033.	2.8	17
49	Risk of SARS-CoV-2 Infection and COVID-19 Severity Associated With Exposure to Nonsteroidal Anti-inflammatory Drugs: Systematic Review and Meta-Analysis. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1521-1533.	2.0	7
50	Drooling rating scales in Parkinson's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 173-180.	2.2	12
51	E09...Magnetic resonance imaging visual analysis of neuromelanin and nigrosome-1 for the assessment of striatonigral dysfunction in huntington's disease. , 2021, , .		0
52	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	3.9	13
53	Clinical Trials for in Parkinson's. <i>Neuromethods</i> , 2021, , 109-135.	0.3	1
54	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. <i>Frontiers in Neurology</i> , 2021, 12, 754016.	2.4	7

#	ARTICLE	IF	CITATIONS
55	Effect of oxygen supply on mortality in acute ST-elevation myocardial infarction: systematic review and meta-analysis. <i>European Journal of Emergency Medicine</i> , 2021, 28, 11-18.	1.1	0
56	High frequency of psychosis in late-stage Parkinson's disease. <i>Clinical Parkinsonism & Related Disorders</i> , 2021, 5, 100119.	0.9	4
57	Deep brain stimulation for dystonia. <i>The Cochrane Library</i> , 2020, 2020, CD012405.	2.8	44
58	Recommendations and levels of evidence in the guidelines of the European Society of Cardiology: current scenario and time trends. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 122-124.	3.0	7
59	Parkinson's Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees. <i>Journal of Parkinson's Disease</i> , 2020, 10, 141-152.	2.8	14
60	Risk of Developing Parkinson Disease in Bipolar Disorder. <i>JAMA Neurology</i> , 2020, 77, 192.	9.0	42
61	Cardiovascular events reported in randomized controlled trials in restless legs syndrome. <i>Sleep Medicine</i> , 2020, 65, 13-17.	1.6	8
62	Does Parkinson's disease increase the risk of cardiovascular events? A systematic review and meta-analysis. <i>European Journal of Neurology</i> , 2020, 27, 288-296.	3.3	32
63	Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies. <i>Heart</i> , 2020, 106, 350-357.	2.9	39
64	Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review. <i>Journal of Vascular Surgery</i> , 2020, 71, 318-327.	1.1	117
65	Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia. <i>Neuroscience</i> , 2020, 424, 58-71.	2.3	2
66	Reply to letter: Does Parkinson's disease increase the risk of cardiovascular events? A systematic review and meta-analysis. <i>European Journal of Neurology</i> , 2020, 27, e12.	3.3	4
67	Levodopa response in later stages of Parkinson's disease: A case-control study. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 160-162.	2.2	3
68	Are genetic and idiopathic forms of Parkinson's disease the same disease?. <i>Journal of Neurochemistry</i> , 2020, 152, 515-522.	3.9	28
69	Physical Activity, Exercise, and Physiotherapy in Parkinson's Disease: Defining the Concepts. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 7-15.	1.5	47
70	Should the Energy Contribution of Commercial Thickeners Be Considered in the Nutrition Plan of Patients With Dysphagia?. <i>Nutrition in Clinical Practice</i> , 2020, 35, 649-654.	2.4	4
71	The "Long and Winding Road" of the Disease-Modifying Effects of Levodopa Has Not Ended Yet. <i>Movement Disorders</i> , 2020, 35, 397-399.	3.9	6
72	Swimming is Compromised in Parkinson's Disease Patients. <i>Movement Disorders</i> , 2020, 35, 365-369.	3.9	9

#	ARTICLE	IF	CITATIONS
73	Measurement Instruments to Assess Functional Mobility in Parkinson's Disease: A Systematic Review. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 129-139.	1.5	28
74	Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis. <i>Primary Care Diabetes</i> , 2020, 14, 213-221.	1.8	12
75	N-terminal Pro-B-type Natriuretic Peptide Levels in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1886-1887.	3.9	2
76	A Standardized MR Imaging Protocol for Parkinsonism. <i>Movement Disorders</i> , 2020, 35, 1745-1750.	3.9	7
77	The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2020, 196, 291-296.	1.7	11
78	Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 100-106.	2.2	23
79	Moving towards home-based community-centred integrated care in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 21-26.	2.2	27
80	Patients and Health Professional's Perspective of Functional Mobility in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 575811.	2.4	8
81	Botulinum toxin type A therapy for hemifacial spasm. <i>The Cochrane Library</i> , 2020, 2020, CD004899.	2.8	6
82	Botulinum toxin type A therapy for blepharospasm. <i>The Cochrane Library</i> , 2020, 2020, CD004900.	2.8	13
83	A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. <i>BMC Neurology</i> , 2020, 20, 432.	1.8	15
84	Botulinum toxin type A therapy for cervical dystonia. <i>The Cochrane Library</i> , 2020, 2020, CD003633.	2.8	23
85	Safety of coffee consumption after myocardial infarction: A systematic review and meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2146-2158.	2.6	14
86	Are Happiness and Well-being the Same Outcome?. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1787-1788.	2.8	0
87	The Role of Architecture and Design in the Management of Parkinson's Disease: A Systematic Review. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1301-1314.	2.8	5
88	Outcome Measures for Evaluating the Effect of a Multidisciplinary Intervention on Axial Symptoms of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 328.	2.4	7
89	Neuromelanin Magnetic Resonance Imaging of the Substantia Nigra in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2020, 9, 143-148.	1.9	2
90	Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1171-1184.	2.8	6

#	ARTICLE	IF	CITATIONS
91	Reply to the letter "We never speak about sudden unexpected death in Parkinson's disease". European Journal of Neurology, 2020, 27, e29.	3.3	0
92	Cardiovascular Adverse Events Reported in Placebo Arm of Randomized Controlled Trials in Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 641-651.	2.8	7
93	Circulating Inflammatory miRNAs Associated with Parkinson's Disease Pathophysiology. Biomolecules, 2020, 10, 945.	4.0	29
94	Strategies to minimize placebo effects in research investigations. International Review of Neurobiology, 2020, 153, 49-70.	2.0	5
95	Challenges and Perspectives in the Management of Late-Stage Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, S75-S83.	2.8	14
96	Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment "the ComOn-study. BMC Geriatrics, 2020, 20, 45.	2.7	19
97	Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease. Expert Review of Clinical Pharmacology, 2020, 13, 85-101.	3.1	4
98	Contingent negative variation: a biomarker of abnormal attention in functional movement disorders. European Journal of Neurology, 2020, 27, 985-994.	3.3	11
99	The Prevalence and Determinants of Neuropsychiatric Symptoms in <scp>Late-Stage</scp> Parkinsonism. Movement Disorders Clinical Practice, 2020, 7, 531-542.	1.5	24
100	The late stage of Parkinson's "results of a large multinational study on motor and non-motor complications. Parkinsonism and Related Disorders, 2020, 75, 91-96.	2.2	25
101	Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1087-1098.	2.8	46
102	Reader response: Beware of deep water after subthalamic deep brain stimulation. Neurology, 2020, 95, 758-759.	1.1	0
103	Huntington's Disease Clinical Trials Corner: June 2019. Journal of Huntington's Disease, 2019, 8, 363-371.	1.9	30
104	Implementation of a Community-Based Exercise Program for Parkinson Patients: Using Boxing as an Example. Journal of Parkinson's Disease, 2019, 9, 615-623.	2.8	16
105	The association of influenza infection and vaccine with myocardial infarction: systematic review and meta-analysis of self-controlled case series. Expert Review of Vaccines, 2019, 18, 1211-1217.	4.4	27
106	Safety Profile of Opicapone in the Management of Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 733-740.	2.8	25
107	A critique of the fragility index. Lancet Oncology, The, 2019, 20, e553.	10.7	8
108	Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. European Journal of Neurology, 2019, 26, 953-960.	3.3	41

#	ARTICLE	IF	CITATIONS
109	International Guidelines for the Treatment of Huntington's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 710.	2.4	98
110	Nocebo response in Parkinson's disease: A systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 13-19.	2.2	18
111	Is lowering stimulation frequency a feasible option for subthalamic deep brain stimulation in Parkinson's disease patients with dysarthria?. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 242-248.	2.2	9
112	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
113	MDS evidence-based review of treatments for essential tremor. <i>Movement Disorders</i> , 2019, 34, 950-958.	3.9	108
114	Morphine in acute coronary syndrome: systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e025232.	1.9	23
115	Dysphagia predicts poor outcome in late-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 73-81.	2.2	26
116	The risks of converting post-hoc findings into primary outcomes in subsequent trials. <i>Annals of Translational Medicine</i> , 2019, 7, S337-S337.	1.7	0
117	Reporting and methodological quality of clinical trials on exercise therapy for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 150-156.	2.2	5
118	Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 490-496.	3.3	25
119	Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 339-345.	2.4	5
120	A rare cause of orofacial dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 122-123.	2.2	1
121	Psychosocial impact of Parkinson's disease-associated dysarthria: Cross-cultural adaptation and validation of the Dysarthria Impact Profile into European Portuguese. <i>Geriatrics and Gerontology International</i> , 2018, 18, 767-774.	1.5	5
122	The launch of opicapone for Parkinson's disease: negatives versus positives. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 331-337.	2.4	22
123	Why Palliative Care Applies to Parkinson's Disease. <i>Movement Disorders</i> , 2018, 33, 750-753.	3.9	12
124	Comments on: "Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease" a randomized controlled trial. <i>European Journal of Neurology</i> , 2018, 25, e4.	3.3	2
125	Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. <i>Neurology</i> , 2018, 90, e1849-e1857.	1.1	40
126	Quality and reporting of guidelines on the diagnosis and management of dystonia. <i>European Journal of Neurology</i> , 2018, 25, 275-283.	3.3	9

#	ARTICLE	IF	CITATIONS
127	Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 111-117.	1.5	27
128	Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. <i>BMC Neurology</i> , 2018, 18, 185.	1.8	27
129	H01â€¦Upcoming international guidelines in huntingtonâ€™s disease. , 2018, , .		0
130	Information Sources and Decision-Making in Neurosurgery: Results of a Survey of Members of the Brazilian Neurosurgery Society. <i>Brazilian Neurosurgery</i> , 2018, 37, 081-087.	0.1	1
131	Erratum - Information Sources and Decision-Making in Neurosurgery: Results of a Survey of Members of the Brazilian Neurosurgery Society. <i>Brazilian Neurosurgery</i> , 2018, 37, 162-162.	0.1	0
132	Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. <i>Movement Disorders</i> , 2018, 33, 1528-1539.	3.9	73
133	Adjunctive Therapies in Parkinsonâ€™s Disease: How to Choose the Best Treatment Strategy Approach. <i>Drugs and Aging</i> , 2018, 35, 1041-1054.	2.7	28
134	Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?. <i>Movement Disorders</i> , 2018, 33, 1228-1235.	3.9	21
135	The placebo response in Parkinson's disease and other movement disorders. <i>Movement Disorders</i> , 2018, 33, 1193-1194.	3.9	2
136	Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. <i>Lancet Neurology</i> , The, 2018, 17, 842.	10.2	7
137	Risk of drowning in people with Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1507-1508.	3.9	13
138	Validation of a Lower Back â€œWearableâ€•Based Sit-to-Stand and Stand-to-Sit Algorithm for Patients With Parkinson's Disease and Older Adults in a Home-Like Environment. <i>Frontiers in Neurology</i> , 2018, 9, 652.	2.4	28
139	Feasibility of using risk prompts to prevent falls, dehydration and pulmonary aspiration in nursing homes: a clinical study protocol. <i>Pilot and Feasibility Studies</i> , 2018, 4, 39.	1.2	1
140	What is Functional Mobility Applied to Parkinsonâ€™s Disease?. <i>Journal of Parkinson's Disease</i> , 2018, 8, 121-130.	2.8	39
141	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. <i>Lancet Neurology</i> , The, 2018, 17, 597-608.	10.2	101
142	Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 16-19.	2.2	11
143	Physician perception versus true efficacy of tetrabenazine for Huntingtonâ€™s disease. <i>Current Medical Research and Opinion</i> , 2018, 34, 1537-1538.	1.9	0
144	The European Physiotherapy Guideline for Parkinson's Disease: Implications for Neurologists. <i>Journal of Parkinson's Disease</i> , 2018, 8, 499-502.	2.8	27

#	ARTICLE	IF	CITATIONS
145	Rationale on the decision-making process for opicapone's bedtime regimen in Parkinson's disease. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-14-36.	0.0	0
146	Cognitive performance in aphasia due to stroke: a systematic review. International Journal on Disability and Human Development, 2017, 16, .	0.2	24
147	Resting and Reemergent Tongue Tremor as Presenting Symptoms of Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 273-274.	1.5	9
148	Mutations in TMEM230 are not a common cause of Parkinson's disease. Movement Disorders, 2017, 32, 302-304.	3.9	14
149	Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?. Movement Disorders Clinical Practice, 2017, 4, 582-585.	1.5	48
150	Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity. Neurology, 2017, 88, 1321-1328.	1.1	99
151	Opicapone for the treatment of Parkinson's disease. Expert Opinion on Pharmacotherapy, 2017, 18, 445-453.	1.8	12
152	Prevalence of Parkinson's disease: a population-based study in Portugal. European Journal of Neurology, 2017, 24, 748-750.	3.3	11
153	Placebo and nocebo responses in restless legs syndrome. Neurology, 2017, 88, 2216-2224.	1.1	46
154	Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 41, 113-117.	2.2	18
155	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. Expert Review of Neurotherapeutics, 2017, 17, 649-659.	2.8	11
156	Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort. Movement Disorders Clinical Practice, 2017, 4, 737-742.	1.5	65
157	Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. Parkinsonism and Related Disorders, 2017, 39, 37-43.	2.2	44
158	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 197.	9.0	146
159	Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. Journal of Parkinson's Disease, 2017, 7, 491-501.	2.8	44
160	Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. Scientific Reports, 2017, 7, 13713.	3.3	79
161	Serum lipid alterations in GBA-associated Parkinson's disease. Parkinsonism and Related Disorders, 2017, 44, 58-65.	2.2	73
162	New perspectives on study designs for evaluating neuroprotection in Parkinson's disease. Movement Disorders, 2017, 32, 1365-1370.	3.9	12

#	ARTICLE	IF	CITATIONS
163	Neuromelanin magnetic resonance imaging of the substantia nigra in <i>LRRK2</i> -related Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1331-1333.	3.9	5
164	Palliative Care for Patients and Families With Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 475-509.	2.0	13
165	The era of the novel oral anticoagulants in Portugal. <i>Revista Portuguesa De Cardiologia (English)</i> Tj ETQq1 1 0.784314 rgBT /Qverlock 0.2	0.2	0
166	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. <i>Movement Disorders</i> , 2017, 32, 1356-1364.	3.9	11
167	Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. <i>Journal of Huntington's Disease</i> , 2017, 6, 157-163.	1.9	50
168	Frenchay dysarthria assessment (FDA-2) in Parkinson's disease: cross-cultural adaptation and psychometric properties of the European Portuguese version. <i>Journal of Neurology</i> , 2017, 264, 21-31.	3.6	15
169	Clinical trials in palliative care: a systematic review of their methodological characteristics and of the quality of their reporting. <i>BMC Palliative Care</i> , 2017, 16, 10.	1.8	56
170	Lack of evidence for a role of genetic variation in TMEM230 in the risk for Parkinson's disease in the Caucasian population. <i>Neurobiology of Aging</i> , 2017, 50, 167.e11-167.e13.	3.1	24
171	The Psychometric Properties of the Voice Handicap Index in People With Parkinson's Disease. <i>Journal of Voice</i> , 2017, 31, 258.e13-258.e18.	1.5	23
172	Comparison of Huntington's Disease in Europe and North America. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 358-367.	1.5	8
173	Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. <i>Frontiers in Neurology</i> , 2017, 8, 35.	2.4	63
174	Algorithm for Turning Detection and Analysis Validated under Home-Like Conditions in Patients with Parkinson's Disease and Older Adults using a 6 Degree-of-Freedom Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , 2017, 8, 135.	2.4	26
175	Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 432.	2.4	50
176	Validation of a Step Detection Algorithm during Straight Walking and Turning in Patients with Parkinson's Disease and Older Adults Using an Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , 2017, 8, 457.	2.4	79
177	A Perspective on Wearable Sensor Measurements and Data Science for Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 677.	2.4	28
178	Meta-research metrics matter: letter regarding article "indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease". <i>Journal of Clinical Movement Disorders</i> , 2017, 4, 19.	2.2	13
179	Automatic Detection of Parkinson's Disease: An Experimental Analysis of Common Speech Production Tasks Used for Diagnosis. <i>Lecture Notes in Computer Science</i> , 2017, , 411-419.	1.3	11
180	The Natural History of Parkinson's Disease. , 2017, , 129-137.		1

#	ARTICLE	IF	CITATIONS
181	Medical Treatment of Parkinson's Disease. , 2017, , 139-156.		0
182	Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials. <i>Frontiers in Neurology</i> , 2016, 7, 27.	2.4	19
183	Spinal Cord Lesion by Minor Trauma as an Early Sign of Multiple System Atrophy. <i>Frontiers in Neurology</i> , 2016, 7, 33.	2.4	0
184	Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. <i>PLoS ONE</i> , 2016, 11, e0157852.	2.5	36
185	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1466-1478.	3.9	44
186	Botulinum toxin type B for cervical dystonia. <i>The Cochrane Library</i> , 2016, 2016, CD004315.	2.8	36
187	Musician's Dystonia as the Initial Presentation of Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 624-625.	1.5	1
188	Twelve-week sensor assessment in Parkinson's disease: Impact on quality of life. <i>Movement Disorders</i> , 2016, 31, 1337-1338.	3.9	20
189	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. <i>European Journal of Neurology</i> , 2016, 23, 772-779.	3.3	12
190	Dysarthria in individuals with Parkinson's disease: a protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark). <i>BMJ Open</i> , 2016, 6, e012885.	1.9	16
191	Association Between Body Mass Index and Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 891.	9.0	1
192	One-year follow-up of opicapone's efficacy and safety in patients with Parkinson's disease and motor fluctuations (BIPARK I). <i>Parkinsonism and Related Disorders</i> , 2016, 22, e100.	2.2	2
193	Reply to letter: Exogenous melatonin for Parkinson's disease: "Waking up" to the need for further trials. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 123-124.	2.2	0
194	Clinical pharmacology review of opicapone for the treatment of Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2016, 6, 349-362.	2.2	17
195	Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. <i>Movement Disorders</i> , 2016, 31, 1649-1657.	3.9	35
196	Are there effective interventions to prevent hospital-acquired Legionnaires' disease or to reduce environmental reservoirs of Legionella in hospitals? A systematic review. <i>American Journal of Infection Control</i> , 2016, 44, e183-e188.	2.3	17
197	Pimavanserin for the treatment of Parkinson's disease psychosis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2115-2124.	1.8	10
198	New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review. <i>Movement Disorders</i> , 2016, 31, 1283-1292.	3.9	119

#	ARTICLE	IF	CITATIONS
199	Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. The Cochrane Library, 2016, 2016, CD004314.	2.8	31
200	Comparison of huntington's disease in europe and North America. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A68.4-A69.	1.9	0
201	Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis. BMJ, The, 2016, 353, i1754.	6.0	157
202	Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease. European Journal of Neurology, 2016, 23, 368-374.	3.3	62
203	A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease. Journal of NeuroEngineering and Rehabilitation, 2016, 13, 24.	4.6	155
204	Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. Clinical Pharmacology in Drug Development, 2016, 5, 232-240.	1.6	29
205	Advanced Parkinson disease patients have impairment in prosody processing. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 208-216.	1.3	17
206	Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis. Parkinsonism and Related Disorders, 2016, 27, 25-34.	2.2	74
207	Continuous leg dyskinesia assessment in Parkinson's disease – clinical validity and ecological effect. Parkinsonism and Related Disorders, 2016, 26, 41-46.	2.2	36
208	Do patients with late-stage Parkinson's disease still respond to levodopa?. Parkinsonism and Related Disorders, 2016, 26, 10-16.	2.2	60
209	Safety of non-vitamin K antagonist oral anticoagulants - coronary risks. Expert Opinion on Drug Safety, 2016, 15, 731-740.	2.4	5
210	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurology, The, 2016, 15, 154-165.	10.2	219
211	Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis. Neurotoxicity Research, 2016, 29, 105-117.	2.7	79
212	Clinical Parameters and Tools for Home-Based Assessment of Parkinson's Disease: Results from a Delphi study. Journal of Parkinson's Disease, 2015, 5, 281-290.	2.8	14
213	Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease. Journal of Parkinson's Disease, 2015, 5, 561-567.	2.8	13
214	Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. Movement Disorders, 2015, 30, 1426-1429.	3.9	33
215	New treatments for levodopa-induced motor complications. Movement Disorders, 2015, 30, 1451-1460.	3.9	95
216	Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. Alimentary Pharmacology and Therapeutics, 2015, 42, 1239-1249.	3.7	51

#	ARTICLE	IF	CITATIONS
217	Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 757-764.	1.9	22
218	Participatory Design in Parkinson's Research with Focus on the Symptomatic Domains to be Measured. <i>Journal of Parkinson's Disease</i> , 2015, 5, 187-196.	2.8	27
219	End of OSLER Test Sessions in Parkinson's Disease do not Correspond to True Sleep Onset: Results from an Exploratory Study. <i>Frontiers in Neurology</i> , 2015, 6, 200.	2.4	2
220	Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. <i>Heart</i> , 2015, 101, 1204-1211.	2.9	106
221	Delayed Parkinsonism after acute chorea due to non-ketotic hyperglycemia. <i>Journal of the Neurological Sciences</i> , 2015, 354, 116-117.	0.6	9
222	"Gunslinger" gait: a new cause of unilaterally reduced arm swing. <i>BMJ</i> , 2015, 351, h6141.	6.0	14
223	Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 815.	3.3	58
224	Pericardial bleeding risk with non-vitamin K oral anticoagulants: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 182, 187-188.	1.7	6
225	Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 111-115.	2.2	26
226	Substantia nigra neuromelanin MRI imaging differentiates essential tremor from Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 953-959.	3.9	69
227	Suicidal behaviors are very rare in antiparkinsonian drug trials. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1008-1009.	2.2	2
228	Tolerability and Acceptability of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Meta-Analysis. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 259-265.	2.2	8
229	Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson's disease: the Barcelona-Lisbon cohort. <i>European Journal of Neurology</i> , 2015, 22, 305-312.	3.3	38
230	Risk of Substantial Intraocular Bleeding With Novel Oral Anticoagulants. <i>JAMA Ophthalmology</i> , 2015, 133, 834.	2.5	29
231	Quantitative home-based assessment of Parkinson's symptoms: The SENSE-PARK feasibility and usability study. <i>BMC Neurology</i> , 2015, 15, 89.	1.8	71
232	Glaucoma Surgery and Anticoagulant Therapy Reply. <i>JAMA Ophthalmology</i> , 2015, 133, 1365.	2.5	1
233	A peripheral pathway to restless legs syndrome? Clues from familial amyloid polyneuropathy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1465-1468.	2.2	6
234	Subthalamic deep brain stimulation effects on odor identification in Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 207-210.	3.3	16

#	ARTICLE	IF	CITATIONS
235	Caffeine and Neuroprotection in Parkinson's Disease. <i>Current Topics in Neurotoxicity</i> , 2015, , 233-272.	0.4	1
236	Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2015, 5, 481-496.	2.2	45
237	Substantia nigra neuromelanin magnetic resonance imaging in <i>de novo</i> Parkinson's disease patients. <i>European Journal of Neurology</i> , 2015, 22, 540-546.	3.3	90
238	How safe is acetaminophen use in patients treated with vitamin K antagonists? A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2015, 135, 58-61.	1.7	14
239	An exome study of Parkinson's disease in Sardinia, a Mediterranean genetic isolate. <i>Neurogenetics</i> , 2015, 16, 55-64.	1.4	20
240	Movement disorders in renal diseases. , 2014, , 172-188.		1
241	Prevalência da anticoagulação oral em doentes com fibrilhação auricular em Portugal: revisão sistemática e meta-análise de estudos observacionais. <i>Revista Portuguesa De Cardiologia</i> , 2014, 33, 555-560.	0.5	16
242	Net clinical benefit outcome should be standardized in trials evaluating antithrombotic drugs: The example of NOACs in atrial fibrillation. <i>International Journal of Cardiology</i> , 2014, 174, 405-406.	1.7	4
243	Oral Anticoagulation for Pulmonary Arterial Hypertension: Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2014, 30, 879-887.	1.7	28
244	Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. <i>Heart</i> , 2014, 100, 550-556.	2.9	91
245	STN-DBS does not change emotion recognition in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 166-169.	2.2	22
246	Thromboembolic risk in the initiation, switch and interruption/re-initiation of oral anticoagulants: Do newcomers improve outcomes? Insights from a meta-analysis of RCTs. <i>International Journal of Cardiology</i> , 2014, 177, 117-119.	1.7	12
247	The prevalence of oral anticoagulation in patients with atrial fibrillation in Portugal: Systematic review and meta-analysis of observational studies. <i>Revista Portuguesa De Cardiologia (English)</i> Tj ETQq1 1 0.784314.2gBT /Overlock 1		
248	The risk of infection with new oral anticoagulants: A meta-analysis. <i>International Journal of Cardiology</i> , 2014, 172, 267-268.	1.7	11
249	Reluctance to start medication for Parkinson's disease: A mutual misunderstanding by patients and physicians. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 608-612.	2.2	5
250	Epidemiology of Levodopa-Induced Dyskinesia. , 2014, , 33-50.		1
251	Recovery after copper-deficiency myeloneuropathy in Wilson's disease. <i>Journal of Neurology</i> , 2013, 260, 1917-1918.	3.6	12
252	Quantitative wearable sensors for objective assessment of Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1628-1637.	3.9	287

#	ARTICLE	IF	CITATIONS
253	Summary of the recommendations of the <sc>EFNS</sc>/<sc>MDS</sc>â€<sc>ES</sc> review on therapeutic management of <sc>P</sc>arkinson's disease. European Journal of Neurology, 2013, 20, 5-15.	3.3	290
254	Warfarin, acetylsalicylic acid and risk of incident atrial fibrillation in patients with heart failure and sinus rhythm: A meta-analysis. International Journal of Cardiology, 2013, 168, 4842-4843.	1.7	0
255	Usefulness of OSLER test in Parkinsonâ€™s disease. Sleep Medicine, 2013, 14, 297-298.	1.6	6
256	Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: Identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants. Parkinsonism and Related Disorders, 2013, 19, 897-900.	2.2	8
257	Wearingâ€œoff phenomena and levodopaâ€œinduced dyskinesias in posttraumatic hemiparkinsonism. Movement Disorders, 2013, 28, 1212-1214.	3.9	3
258	Caffeine does not increase the risk of atrial fibrillation: a systematic review and meta-analysis of observational studies. Heart, 2013, 99, 1383-1389.	2.9	75
259	Branded Versus Generic Clopidogrel in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology, 2013, 61, 277-282.	1.9	19
260	Referral to rehabilitation in Parkinson's disease: who, when and to what end?. Arquivos De Neuro-Psiquiatria, 2013, 71, 967-972.	0.8	9
261	Immunogenicity and Long-Term Efficacy of Botulinum Toxin Type B in the Treatment of Cervical Dystonia. Clinical Neuropharmacology, 2012, 35, 215-223.	0.7	25
262	An evidence-based approach in the treatment of Huntingtonâ€™s disease. Parkinsonism and Related Disorders, 2012, 18, 316-320.	2.2	50
263	Associated movement disorders in orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 725-729.	1.9	46
264	Late-stage Parkinson disease. Nature Reviews Neurology, 2012, 8, 435-442.	10.1	183
265	A proofâ€œofâ€œconcept, randomized, placeboâ€œcontrolled, multiple crossâ€œovers (nâ€œofâ€œ1) study of naftazone in Parkinsonâ€™s disease. Fundamental and Clinical Pharmacology, 2012, 26, 557-564.	1.9	27
266	Paralytic shellfish poisoning due to ingestion of Gymnodinium catenatum contaminated cockles â€œ Application of the AOAC HPLC Official Method. Toxicon, 2012, 59, 558-566.	1.6	41
267	Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Functional Neurology, 2012, 27, 225-30.	1.3	14
268	What motivates Parkinsonâ€™s disease patients to enter clinical trials?. Parkinsonism and Related Disorders, 2011, 17, 667-671.	2.2	26
269	Has â€œlevodopaâ€œinduced neuropathyâ€œbeen reported in Parkinson's disease clinical trials?. Movement Disorders, 2011, 26, 1966-1967.	3.9	9
270	Temporal stability of the Unified Dyskinesia Rating Scale. Movement Disorders, 2011, 26, 2556-2559.	3.9	20

#	ARTICLE	IF	CITATIONS
271	Convergence of miRNA Expression Profiling, α -Synuclein Interacton and GWAS in Parkinson's Disease. PLoS ONE, 2011, 6, e25443.	2.5	235
272	Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. Journal of Neurology, 2010, 257, 1524-1532.	3.6	106
273	How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Movement Disorders, 2010, 25, 534-541.	3.9	728
274	Skin cancer and Parkinson's disease. Movement Disorders, 2010, 25, 139-148.	3.9	43
275	Prescribing patterns of antiparkinsonian agents in Europe. Movement Disorders, 2010, 25, 1053-1060.	3.9	24
276	Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations. Movement Disorders, 2010, 25, 2704-2716.	3.9	214
277	Adjunctive entacapone therapy increases risk of dyskinesia. Nature Reviews Neurology, 2010, 6, 590-591.	10.1	5
278	Pharmacotherapy in Parkinson's disease: case studies. Therapeutic Advances in Neurological Disorders, 2010, 3, 117-126.	3.5	5
279	ADAGIO trial hints that rasagiline slows disease progression. Nature Reviews Neurology, 2010, 6, 126-128.	10.1	11
280	Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review. Parkinsonism and Related Disorders, 2010, 16, 237-242.	2.2	150
281	A Double-blind, Randomized, Placebo and Active-controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease. CNS Neuroscience and Therapeutics, 2010, 16, 337-347.	3.9	21
282	Eslicarbazepine acetate: a new option for the treatment of focal epilepsy. Expert Opinion on Investigational Drugs, 2009, 18, 221-229.	4.1	25
283	A multimodal approach to physical therapy in Parkinson's disease: Optimizing strategies. Movement Disorders, 2009, 24, 946-946.	3.9	0
284	Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism and Related Disorders, 2009, 15, 466-467.	2.2	31
285	GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 703-705.	2.2	22
286	Therapeutic interventions for symptomatic treatment in Huntington's disease. The Cochrane Library, 2009, , CD006456.	2.8	91
287	Therapeutic interventions for disease progression in Huntington's disease. The Cochrane Library, 2009, , CD006455.	2.8	52
288	Safety of Chiropractic Interventions. Spine, 2009, 34, E405-E413.	2.0	103

#	ARTICLE	IF	CITATIONS
289	Current and Future Therapeutic Strategies for Parkinsons Disease. Current Pharmaceutical Design, 2009, 15, 3968-3976.	1.9	11
290	Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. Journal of Neurology, 2008, 255, 545-550.	3.6	51
291	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, The, 2008, 7, 583-590.	10.2	1,340
292	The Placebo Response in Studies of Acute Migraine. Journal of Pediatrics, 2008, 152, 527-533.e1.	1.8	52
293	Dopamine agonist therapy in early Parkinson's disease. The Cochrane Library, 2008, , CD006564.	2.8	120
294	Hyposmia in G2019S LRRK2-related parkinsonism. Neurology, 2008, 71, 1021-1026.	1.1	82
295	Treatment options for non-motor symptoms in late-stage Parkinson's disease. Expert Opinion on Pharmacotherapy, 2008, 9, 523-535.	1.8	18
296	Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease. Clinical Neuropharmacology, 2008, 31, 2-18.	0.7	30
297	ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology, 2007, 68, 1557-1562.	1.1	312
298	Piribedil versus levodopa in early Parkinson's disease. The Cochrane Library, 2007, , .	2.8	0
299	Chiropractic manipulation: Reasons for concern?. Clinical Neurology and Neurosurgery, 2007, 109, 922-925.	1.4	19
300	The management of cervical dystonia. Expert Opinion on Pharmacotherapy, 2007, 8, 129-140.	1.8	23
301	Therapeutic interventions for daytime somnolence in Parkinson's disease. The Cochrane Library, 2007, , .	2.8	0
302	High prevalence ofLRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. Movement Disorders, 2007, 22, 1194-1201.	3.9	76
303	Skin cancers and precancerous lesions in Parkinson's disease patients. Movement Disorders, 2007, 22, 1471-1475.	3.9	18
304	Sneeze as a precipitating factor of cerebral venous thrombosis. European Journal of Neurology, 2007, 14, e7-e8.	3.3	8
305	Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers. European Journal of Neurology, 2006, 13, 209-214.	3.3	80
306	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. European Journal of Human Genetics, 2006, 14, 322-331.	2.8	152

#	ARTICLE	IF	CITATIONS
307	Putaminal petechial haemorrhage as the cause of non-ketotic hyperglycaemic chorea: a neuropathological case correlated with MRI findings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 549-550.	1.9	46
308	Botulinum toxin type A therapy for hemifacial spasm. <i>The Cochrane Library</i> , 2005, , CD004899.	2.8	47
309	A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. <i>Lancet, The</i> , 2005, 365, 412-415.	13.7	449
310	Clinical comparability of marketed formulations of botulinum toxin. <i>Movement Disorders</i> , 2004, 19, S129-S136.	3.9	111
311	Botulinum toxin type A therapy for blepharospasm. <i>The Cochrane Library</i> , 2004, , CD004900.	2.8	52
312	Essential tremor. <i>Clinical Evidence</i> , 2004, , 1674-86.	0.2	1
313	Limitations of current Parkinson's disease therapy. <i>Annals of Neurology</i> , 2003, 53, S3-S15.	5.3	250
314	Essential tremor. <i>Clinical Evidence</i> , 2003, , 1421-31.	0.2	0
315	Effect of ropinirole on sleep onset: A randomized, placebo-controlled study in healthy volunteers. <i>Neurology</i> , 2002, 58, 460-462.	1.1	71
316	Evidence-based medicine (EBM) applied to Parkinson's disease treatment. <i>Parkinsonism and Related Disorders</i> , 2002, 9, 7-13.	2.2	4
317	Sleep Attacks and Antiparkinsonian Drugs: A Pilot Prospective Pharmacoepidemiologic Study. <i>Clinical Neuropharmacology</i> , 2001, 24, 181-183.	0.7	85
318	Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients. <i>Journal of Neurology</i> , 2001, 248, 426-427.	3.6	44
319	Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2000, 13, 431-436.	3.6	13
320	Sleep attacks and Parkinson's disease treatment. <i>Lancet, The</i> , 2000, 355, 1333-1334.	13.7	220
321	DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A "Dysport and Botox" assuming a ratio of 4:1. <i>Movement Disorders</i> , 1997, 12, 1013-1018.	3.9	220
322	Therapeutic interventions for sleep disorders in Parkinson's disease. <i>The Cochrane Library</i> , 0, , .	2.8	0
323	Piribedil for symptomatic management of Parkinson's disease. <i>The Cochrane Library</i> , 0, , .	2.8	0
324	Piribedil for levodopa-induced complications in Parkinson's disease. <i>The Cochrane Library</i> , 0, , .	2.8	0